Roger Song
Stock Analyst at Jefferies
(4.04)
# 557
Out of 5,117 analysts
50
Total ratings
47.62%
Success rate
16.29%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Roger Song
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NKTR Nektar Therapeutics | Maintains: Buy | $99 → $121 | $44.49 | +171.97% | 12 | Nov 26, 2025 | |
| ORKA Oruka Therapeutics | Initiates: Buy | $45 | $31.70 | +41.96% | 1 | Nov 13, 2025 | |
| GYRE Gyre Therapeutics | Initiates: Buy | $16 | $7.26 | +120.39% | 1 | Oct 10, 2025 | |
| UTHR United Therapeutics | Maintains: Buy | $432 → $564 | $507.16 | +11.21% | 1 | Sep 2, 2025 | |
| BMEA Biomea Fusion | Initiates: Buy | $5 | $1.32 | +278.79% | 1 | Aug 28, 2025 | |
| ATYR aTyr Pharma | Maintains: Buy | $9 → $17 | $0.74 | +2,188.64% | 2 | Aug 22, 2025 | |
| MBX MBX Biosciences | Assumes: Buy | $36 | $30.90 | +16.50% | 1 | Aug 15, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Maintains: Buy | $45 → $54 | $42.00 | +28.57% | 3 | Jul 29, 2025 | |
| REPL Replimune Group | Maintains: Buy | $31 → $6 | $9.96 | -39.76% | 2 | Jul 22, 2025 | |
| CVAC CureVac | Downgrades: Hold | $7 → $5 | $4.30 | +16.28% | 1 | Jun 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $1.66 | +261.45% | 1 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $4.41 | +58.73% | 1 | Mar 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $245 | $252.17 | -2.84% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $26 | $17.77 | +46.31% | 1 | Feb 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $42 → $7 | $13.88 | -49.57% | 2 | Dec 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $32 → $28 | $10.63 | +163.41% | 2 | Nov 21, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2 → $7 | $3.03 | +131.02% | 1 | Nov 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $89 | $80.33 | +10.79% | 1 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $31 → $25 | $6.83 | +266.03% | 2 | Oct 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $41 | $19.30 | +112.44% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $42.49 | -17.63% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $129 | $46.97 | +174.64% | 1 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $2.5 → $8 | $4.39 | +82.23% | 3 | May 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $97 | $104.10 | -6.82% | 1 | Apr 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $110 | $37.18 | +195.86% | 1 | Mar 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $35 | $3.86 | +806.74% | 1 | Aug 31, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9 | $2.45 | +267.35% | 1 | Jul 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $7.70 | +3.90% | 2 | Dec 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $210 | $11.49 | +1,727.68% | 1 | Sep 2, 2020 |
Nektar Therapeutics
Nov 26, 2025
Maintains: Buy
Price Target: $99 → $121
Current: $44.49
Upside: +171.97%
Oruka Therapeutics
Nov 13, 2025
Initiates: Buy
Price Target: $45
Current: $31.70
Upside: +41.96%
Gyre Therapeutics
Oct 10, 2025
Initiates: Buy
Price Target: $16
Current: $7.26
Upside: +120.39%
United Therapeutics
Sep 2, 2025
Maintains: Buy
Price Target: $432 → $564
Current: $507.16
Upside: +11.21%
Biomea Fusion
Aug 28, 2025
Initiates: Buy
Price Target: $5
Current: $1.32
Upside: +278.79%
aTyr Pharma
Aug 22, 2025
Maintains: Buy
Price Target: $9 → $17
Current: $0.74
Upside: +2,188.64%
MBX Biosciences
Aug 15, 2025
Assumes: Buy
Price Target: $36
Current: $30.90
Upside: +16.50%
Kiniksa Pharmaceuticals International,
Jul 29, 2025
Maintains: Buy
Price Target: $45 → $54
Current: $42.00
Upside: +28.57%
Replimune Group
Jul 22, 2025
Maintains: Buy
Price Target: $31 → $6
Current: $9.96
Upside: -39.76%
CureVac
Jun 13, 2025
Downgrades: Hold
Price Target: $7 → $5
Current: $4.30
Upside: +16.28%
Apr 1, 2025
Initiates: Buy
Price Target: $6
Current: $1.66
Upside: +261.45%
Mar 14, 2025
Initiates: Buy
Price Target: $7
Current: $4.41
Upside: +58.73%
Mar 5, 2025
Initiates: Buy
Price Target: $245
Current: $252.17
Upside: -2.84%
Feb 25, 2025
Initiates: Buy
Price Target: $26
Current: $17.77
Upside: +46.31%
Dec 9, 2024
Downgrades: Hold
Price Target: $42 → $7
Current: $13.88
Upside: -49.57%
Nov 21, 2024
Maintains: Buy
Price Target: $32 → $28
Current: $10.63
Upside: +163.41%
Nov 19, 2024
Upgrades: Buy
Price Target: $2 → $7
Current: $3.03
Upside: +131.02%
Oct 23, 2024
Initiates: Buy
Price Target: $89
Current: $80.33
Upside: +10.79%
Oct 16, 2024
Maintains: Buy
Price Target: $31 → $25
Current: $6.83
Upside: +266.03%
Oct 11, 2024
Initiates: Buy
Price Target: $41
Current: $19.30
Upside: +112.44%
Oct 8, 2024
Initiates: Buy
Price Target: $35
Current: $42.49
Upside: -17.63%
Sep 3, 2024
Maintains: Buy
Price Target: $108 → $129
Current: $46.97
Upside: +174.64%
May 6, 2024
Upgrades: Buy
Price Target: $2.5 → $8
Current: $4.39
Upside: +82.23%
Apr 17, 2024
Initiates: Buy
Price Target: $97
Current: $104.10
Upside: -6.82%
Mar 7, 2024
Initiates: Buy
Price Target: $110
Current: $37.18
Upside: +195.86%
Aug 31, 2022
Maintains: Buy
Price Target: $30 → $35
Current: $3.86
Upside: +806.74%
Jul 29, 2022
Initiates: Buy
Price Target: $9
Current: $2.45
Upside: +267.35%
Dec 1, 2021
Initiates: Buy
Price Target: $8
Current: $7.70
Upside: +3.90%
Sep 2, 2020
Initiates: Buy
Price Target: $210
Current: $11.49
Upside: +1,727.68%